Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from December 2022.
antitrust
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy -
Read more: Stop Playing Health Care Antitrust Whack-A-Mole Stop Playing Health Care Antitrust Whack-A-Mole
The Biden/Harris administration appears uniquely poised to implement a comprehensive initiative to address health care consolidation.
-
Read more: Is It Time to Reverse Health System Consolidation? Is It Time to Reverse Health System Consolidation?
Concentrated corporate power currently impedes affordable provision of health care across the state of Massachusetts.
-
Read more: 3 Challenges to Patents on Therapeutic Monoclonal Antibodies 3 Challenges to Patents on Therapeutic Monoclonal Antibodies
Three developments may have effects on the use of patents to fend off competition for therapeutic monoclonal antibodies.
-
Read more: When “Pay-for-Delay” Becomes “Delay-Without-Pay”: Humira Antitrust Claims When “Pay-for-Delay” Becomes “Delay-Without-Pay”: Humira Antitrust Claims
In this post, I explore several problematic aspects of the court’s reasoning for rejecting the claims of pay-for-delay and market allocation.
-
Read more: Year in Review: Biosimilars Year in Review: Biosimilars
In November 2020, the FDA released its most recent draft guidance for industry on biosimilarity and interchangeability
-
Read more: AbbVie Wins First Round in Humira Antitrust Lawsuit AbbVie Wins First Round in Humira Antitrust Lawsuit
The purpose of the secondary patent filings was to assemble a thicket of patents, 132 in all, to prohibit competition from biosimilar companies.
